Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib

doi:10.3748/wjg.v24.i4.484

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8133)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

475

WORD

394

HTML

4258

Figures (1-2)

243

Tables (1-5)

244

Sum=5614

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1030

Download

1489

Sum=2519

Jan 28, 2018 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jan 28, 2018; 24(4): 484-493
Published online Jan 28, 2018. doi: 10.3748/wjg.v24.i4.484

Table 4 Adverse events related to sorafenib

Adverse event	All events	Grade 1-2 events	Grade 3 or higher events
Hand-foot skin reactions	78 (82.1)	67 (70.5)	11 (11.6)
Diarrhea	71 (74.7)	62 (65.3)	9 (9.5)
Hypertension	10 (10.5)	8 (8.4)	2 (2.1)
Alopecia	29 (30.5)	29 (30.5)	0
Fatigue	29 (30.5)	29 (30.5)	0
Voice change	1 (1.1)	1 (1.1)	0
Gastrointestinal hemorrhage	7 (7.4)	0	7 (7.4)
Epistaxis	1 (1.1)	1 (1.1)	0

Data shown are number of events. Percentages are in parentheses and were calculated by using number of patients as denominator n (%).

Citation: Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018; 24(4): 484-493
URL: https://www.wjgnet.com/1007-9327/full/v24/i4/484.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i4.484